Operating Income (Loss) in USD of RECURSION PHARMACEUTICALS, INC. from 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Recursion Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and change rate from 2019 to Q3 2025.
  • Recursion Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$172M, a 75.1% decline year-over-year.
  • Recursion Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$724M, a 83.6% decline year-over-year.
  • Recursion Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$479M, a 36.8% decline from 2023.
  • Recursion Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$350M, a 42.5% decline from 2022.
  • Recursion Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$246M, a 34.4% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

RECURSION PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$724M -$172M -$73.8M -75.1% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 -$650M -$176M -$75.7M -75.3% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025
Q1 2025 -$574M -$191M -$95M -98.6% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025
Q4 2024 -$479M -$184M -$84.8M -85.8% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025
Q3 2024 -$394M -$98.4M +$1.2M +1.2% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 -$395M -$101M -$18.8M -23% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025
Q1 2024 -$377M -$96.3M -$26.5M -37.9% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025
Q4 2023 -$350M -$98.9M -$37.9M -62.2% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025
Q3 2023 -$312M -$99.6M -$37M -59.1% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 -$275M -$81.7M -$15.5M -23.5% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$260M -$69.9M -$13.9M -24.8% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 -$246M -$61M +$3.98M +6.12% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025
Q3 2022 -$250M -$62.6M -$16.2M -34.9% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$234M -$66.2M -$25.3M -61.7% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023
Q1 2022 -$208M -$56M -$25.5M -83.6% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023
Q4 2021 -$183M -$65M -$39.4M -154% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024
Q3 2021 -$143M -$46.4M -$23.9M -106% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022
Q2 2021 -$119M -$40.9M -$22.7M -125% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 -$96.8M -$30.5M -$12.1M -66.2% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022
Q4 2020 -$84.6M -$25.6M 01 Oct 2020 31 Dec 2020 10-K 27 Feb 2023
Q3 2020 -$22.5M 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021
Q2 2020 -$18.2M 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021
Q1 2020 -$18.3M 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021

RECURSION PHARMACEUTICALS, INC. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$479M -$129M -36.8% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025
2023 -$350M -$104M -42.5% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025
2022 -$246M -$63M -34.4% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025
2021 -$183M -$98.2M -116% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024
2020 -$84.6M -$22.2M -35.5% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023
2019 -$62.4M 01 Jan 2019 31 Dec 2019 10-K 23 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.